XyloCor Therapeutics
King Of Prussia
About XyloCor Therapeutics
XyloCor Therapeutics is a biotechnology company focused on creating gene therapies for patients with advanced coronary artery disease. Its lead product candidate, XC001, is in clinical development for patients with refractory angina, addressing significant unmet medical needs. The company aims to improve patient outcomes through innovative gene therapy technologies developed in collaboration with Weill Cornell Medical College.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $107.1M
- Funding stage: Early Stage Venture
- Last round: Series B (Jan 2025)
- Website: xylocor.com
- Phone: 888-290-0081
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/xylocor-therapeutics-66728 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.